July 29, 2019 09:05 AM EDTUpdated 09:44 AM
R&D

Af­ter paint­ing a poor safe­ty pro­file, Pfiz­er and Eli Lil­ly are shoot­ing for a new pain drug OK any­way

John Carroll

Editor & Founder

Months af­ter an­a­lysts wrote off the NGF pain drug tanezum­ab as a per­pet­u­al los­er, Pfiz­er and Eli Lil­ly have de­cid­ed to push ahead and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times